Selegiline for Alzheimer's disease (Q24250198)

29 July 2017

0 references

1 reference

title

Selegiline for Alzheimer's disease (English)

1 reference

29 July 2017

1 reference

1

0 references

author name string

Leon Flicker

series ordinal

2

0 references

J Birks

series ordinal

1

1 reference

PubMed ID

29 July 2017

L Flicker

series ordinal

2

1 reference

29 July 2017

20 January 2003

0 references

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

1 reference

29 July 2017

CD000442

1 reference

29 July 2017

2

1 reference

L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results.

29 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

L-deprenyl in Alzheimer's disease: cognitive and behavioral effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

The Global Deterioration Scale for assessment of primary degenerative dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

Assessing patient dependence in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

THE NURSES' OBSERVATION SCALE FOR INPATIENT EVALUATION: A NEW SCALE FOR MEASURING IMPROVEMENT IN CHRONIC SCHIZOPHRENIA

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Selegiline in the treatment of behavioural disturbance in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Cognitive effects of L-deprenyl in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Cornell Scale for Depression in Dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD000442

1 reference

7 January 2021

L-deprenyl and physostigmine for the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

A new rating scale for dementia syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Brief information on an early phase-II study with deprenyl in demented patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Bias in treatment assignment in controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Alpha-tocopherol and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000442

7 January 2021

10.1002/14651858.CD000442

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2050449

PubMed ID

29 July 2017

2050449

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference

2050449

1 reference

PubMed ID